Cancure Limited Investor Presentation Series A Capital Raise 01 - - PowerPoint PPT Presentation

Cancure Limited Series A Capital Raise – November 2015

Cancure Limited Investor Presentation Series A Capital Raise 01 November 2015

Cancure Limited Series A Capital Raise – November 2015

DISCLAIMER

Cancure and its officers, employees, consultants and advisors:

• Do not make any guarantee, representation or warranty, either expressed or implied concerning the accuracy, completeness or

reliability of the information contained in this Investor Presentation or accept any responsibility for errors or omissions in any information contained in this Investor Presentation or the future performance of Cancure; and

• Disclaim and exclude all liability for losses including consequential loss, claims, damages and costs of whatever nature arising in

any way out of or in connection with the provision of the Investor Presentation (or any accompanying or other information) and any inaccuracy or incompleteness or reliance by any person on any of it. Specifically, Cancure does not warrant or represent that the information contained in this Investor Presentation has been audited, except where specifically stated otherwise and where required by law. The Investor Presentation is intended for review in conjunction with Cancure’s complete Information Memorandum. Recipients should seek appropriate professional advice in reviewing the Investor Presentation and the Information Memorandum, and in evaluating the suitability of the investment. The Investor Presentation may include forward-looking statements, which reflect various assumptions. Those assumptions may or may not prove to be correct. Actual results may be materially affected by changes in economic and other circumstances. The reliance that recipients place upon such information is a matter for their own commercial judgement. All warranties, conditions, liabilities or representations in relation to information or advice contained in this Investor Presentation are expressly negated and excluded to the maximum extent permitted by law. The recipient agrees, to the fullest extent permitted by law that he/she shall not seek to sue or hold Cancure or its officers, employees, consultants and advisors liable in any respect by reason of provision of the Investor Presentation.

Cancure Limited Series A Capital Raise – November 2015

CONTENTS (* indicates content redacted for website publication)

Investment Highlights Summary of SERIES A Offer * Oncology Drug Market Market Positioning of Cancure’s Pipeline Lead Product Candidates CNC118, CNC225, CNC332 Board & Management Use of Funds * Value Realisation & Growth Projections * Offer Timetable * Contact Details Appendices Development Plan & Financials * Ownership Interests & Corporate Structure *

High magnification image of a cancer-fighting human T cell (US NIH).

Cancure Limited Series A Capital Raise – November 2015

• Cancure Limited is a clinical-stage cancer drug development company.
• Over A$15 million of investment and R&D funding in the past decade.
• Three drug candidates in the pipeline, each with billion dollar potential.
• Pilot Phase 1 human clinical trial completed for therapeutic cancer vaccine.
• Ideally positioned in the immuno-oncology revolution.
• Robust roadmap to commercialisation.
• Experienced scientific experts and business team.
• Dr. Ian Nisbet (CSL, Millennium) appointed CEO.
• Opportunity for significant value uplift in 3-5 year time horizon.
• IP protected by worldwide patents covering major markets.
• Investment leveraged by up to 45% with Australian R&D tax incentive.

INVESTMENT HIGHLIGHTS

Cancure Limited Series A Capital Raise – November 2015

ONCOLOGY DRUG MARKET

• Oncology is the top selling drug category in developed markets at ~ US$100 billion per annum.
• Average cost per month for a branded oncology drug in the United States is ~ US$10,000.
• Targeted and immunotherapy gaining market share, eroding dominant share of conventional chemotherapy.
• Cancer vaccines to see a compound annual growth rate of over 27% through 2019 (Infiniti Research).

The global oncology drugs market is expected to reach US$119.3 billion by 2020, growing at a CAGR

• f

approximately 7% between 2015 and 2020. Shifting of key drivers of growth in the global oncology drugs market from 2014 (grey) to 2020 (red). US$ billions

87.6 93.2 99.1 105.4 112.2 119.3 126.9 135 143.7 2015 2016 2017 2018 2019 2020 2021 2022 2023

Surge of Biologics and Targeted Therapies High drug development costs coupled with risk of failure Adverse effects of chemotherapy Collaborations and Acquisitions Fast Track Designations Approvals and Clinical Trials Increasing Investment from Government, Public and Private Sectors Rising disposable incomes and consumer healthcare expenditures

Cancure Limited Series A Capital Raise – November 2015

IMMUNO-ONCOLOGY REVOLUTION

Conventional Chemotherapy (1950s – present) Targeted drug therapies (late 1990s – present) Immunotherapies (Revolution happening now)

• Cancure is developing two immunotherapy drug candidates and one targeted cancer drug candidate.
• Ideally positioned in the current immuno-oncology revolution – from cancer treatments to cancer cures.

Cancure Limited Series A Capital Raise – November 2015

IMMUNO-ONCOLOGY REVOLUTION

“This year marks a turning point in cancer, as long-sought efforts to unleash the immune system against tumors are paying off. That's what made Science's… Breakthrough of the Year. In celebrating cancer immunotherapy… harnessing the immune system to battle tumors… to transform biological insights into lifesaving drugs…” Jennifer Couzin-Frankel, Staff Writer Science Magazine, 20 Dec 2013

Cancure Limited Series A Capital Raise – November 2015

RECENT ONCOLOGY DEALS

BIOTECH PHARMA YEAR MODALITY INDICATION STAGE PRICE (US)

Jiangsu Hengrui Incyte 2015 Antibody Solid tumours Ph1 $25M Upfront (L) $770M Milestones Intrexon Merck 2015 CAR T-cell Immuno-

• ncology

Discovery $115M Upfront (L) $826M Milestones Flexus BMS 2015 Small molecule Immuno-

• ncology

Preclinical discovery $1.25B (TS) $800M Upfront Aurigene Curis 2015 Small molecule Melanoma, NSCLC Ph1/2 $30M Upfront (L) $52M Milestones* Aduro Biotech Novartis 2015 Small molecule Immuno-

• ncology

Preclinical $200M Upfront (L) $500M Milestones Cellectis Pfizer 2014 CAR T-cell Immuno-

• ncology

Preclinical $80M Upfront (L) $185M Milestones* Definiens Medimmune 2014 Biomarkers Immuno-

• ncology

Discovery $150M (TS) + Milestones Aduro Biotech J&J Janussen 2014 LADD vaccine Mesothelioma, Prostate Preclinical $365M Upfront (L) + Milestones Oryzon Roche 2014 Small molecule Acute myeloid leukemia Ph1 $21M Upfront (L) >$500M Milestones * Per drug candidate; (L) = License; (TS) = Trade Sale

Cancure Limited Series A Capital Raise – November 2015

CANCURE PIPELINE

• Series A to fund the first 18 months of development; planned Series B to fund the next 18 months of clinical

trials for each lead product candidate to achieve maximal value uplift.

• CNC118 has completed a pilot Phase 1 human clinical trial. Series A will fund the manufacturing of CNC118 for

entry into a Phase 1/2 human clinical trial; Series B will fund that clinical trial.

• CNC225 and CNC332 have demonstrated efficacy in animal models. Series A will fund their formal preclinical

development for entry into Phase 1 human clinical trials; Series B will fund both clinical trials.

Cancure Limited Series A Capital Raise – November 2015

LEAD PRODUCT CANDIDATES

Cancure Limited Series A Capital Raise – November 2015

• Genvax cancer vaccines “train” natural immune T-cells to detect and eliminate

cancer cells.

• Generates many T-cell populations against various cancer cell targets, with

potential for immunological memory to prevent cancer recurrence.

• Being developed for the treatment of advanced-stage malignant melanoma.
• Off-the-shelf therapy due to high genetic compatibility with cancer patients.
• Designed for combination with immune checkpoint inhibitors such as Keytruda

and with other cancer drugs to increase patient response rates.

• CNC118 was well tolerated in a pilot, Ph1 human clinical trial with nine patients.
• As a single agent, CNC118 showed 44% clinical benefit.
• Proprietary manufacturing methods and broad patent coverage.

GENVAX VIDEO - http://cancure.com/therapies/genvax-cnc118/

GENVAX PROGRAM LEAD CANDIDATE - CNC118

Cancure Limited Series A Capital Raise – November 2015

RECENT CANCER VACCINE DEALS

Year Biotech Pharma Vaccine Indication Stage Deal 2015 Gritstone Oncology n/a Neoantigens Lung Preclinical VC Funding US$102M (Versant Ventures) 2015 Bavarian Nordic BMS Prostvac Prostate Ph3 Licence US$60M Upfront US$915M Milestones 2015 Dendreon Valeant Provenge Prostate Market Acquisition US$495M 2015 Aduro n/a GVAX CRS-207 Pancreatic Ph2 IPO US$119M IPO 2015 Northwest Bio n/a DCVax-L Glioblastoma Ph3 VC Funding US$65M (Neil Woodford) 2014 CureVac Boehringer Ingelheim CV9202 Lung Preclinical Licence US$45M Upfront US$556M Milestones 2013 Inovio Roche INO-5150 Prostate Preclinical Licence US$10M Upfront US$412M Milestones 2011 BioVex Amgen T-Vec Head & neck, Breast, Colorectal, Pancreatic Ph3 Acquisition US$425M Upfront US$575M Milestones

Cancure Limited Series A Capital Raise – November 2015

• Galectins are proteins that block cancer-fighting immune cells. Galectin-1 is

secreted by cancer cells, and is highly expressed in metastatic tumours.

• CNC225 blocks the cancer-promoting activity of galectin-1, and also inhibits

the growth of blood vessels to the tumour.

• High potency analog of a clinically validated drug with minimal side-effects.
• Patent protected in major markets for use in cancer therapy.
• Encouraging efficacy in mouse models of colon and breast cancer.
• 100% survival of mice treated with triple combination of a Genvax-type

vaccine and CNC225 with an immune checkpoint inhibitor.

• Galectins are relatively unexploited drug targets.

GALECTIN VIDEO - http://cancure.com/therapies/galectin-cnc225/

GALECTIN PROGRAM LEAD CANDIDATE - CNC225

Cancure Limited Series A Capital Raise – November 2015

“ALL ABOUT” DRUG COMBINATIONS

“It will likely be all about combinations: immunotherapy combinations or targeted combinations. We will also be figuring out the sequencing of those combinations… Even now, we can begin qualifying and quantifying patients in terms of complete responses [cures]… … Because of the successes with immune checkpoint inhibitors [ICIs] in cancer immunotherapy, many new agents and strategies, including combination approaches, are being developed at a fast pace.”

• F. Stephen Hodi, Jr., MD

Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School

Cancure Limited Series A Capital Raise – November 2015

TRIPLE COMBINATION THERAPY

• In vivo demonstration of synergistic effects of combining a prototype Genvax vaccine (mouse) and

CNC225 with immune checkpoint inhibitor (ICI) in a mouse model of colon cancer. In this well established model, survival to 60 days is considered an experimental cure.

• The triple combination cured all (100%) of the mice with colon cancer. In contrast, treatment with

ICI alone only cured 30% of the mice. Mouse model of colon cancer Days of survival % Surviving mice

100% of the mice were cured with the triple combination. 30% of the mice were cured with ICI alone. Triple: ICI + Prototype Genvax vaccine + CNC225 Prototype Genvax vaccine + CNC225 ICI alone Control untreated

Cancure Limited Series A Capital Raise – November 2015

GLOBAL PIPELINE OF EXPERIMENTAL DRUGS TARGETING GALECTINS

Program Company Stage Indications Modality GCS-100 La Jolla Pharmaceuticals

Ph2

Renal disease, Cancer Complex polysaccharide LJPC-1010 La Jolla Pharmaceuticals

Preclinical

Non-alcoholic steatohepatitis Complex polysaccharide GR-MD-02 Galectin Therapeutics

Ph1

Liver Fibrosis, Melanoma Novel carbohydrates GM-CT-01 Galectin Therapeutics

Ph1

Melanoma Novel carbohydrates TD139 * Galecto Biotech / BMS

Ph2

Pulmonary fibrosis Small molecule inhibitor OTX008 ** Oncoethix

Ph1

Advanced solid tumours Calixarene compound Galectin-3C Mandalmed

Preclinical

Cancer Truncated galectin-3 MP-3546 MediaPharma

Preclinical

Cancer Bispecific antibody * Subject of a US$444M option deal with Bristol Myers Squibb (BMS) in November 2014. ** Oncoethix was acquired by Merck in 2014 for US$110M upfront and $265M in milestones.

Cancure Limited Series A Capital Raise – November 2015

• CNC332 is a targeted anti-cancer agent.
• Vitamin E analog that selectively targets tumour cells’ mitochondria, the cellular

subcomponents that produce bioenergy.

• Mitochondria are critical for cell survival, and are therefore recognised as

potentially valuable drug targets for cancer therapy.

• CNC332 causes cancer cells to self-destruct by natural “apoptosis”, and has

demonstrated anti-cancer efficacy in mouse models.

• One case of compassionate use of Mitocans prototype CNC331 for treatment
• f inoperable mesothelioma – oncologist reported “dramatic clinical response”.
• Request from US National Cancer Institute (NCI) to conduct studies at NCI.
• 2 patent families with coverage in major markets.
• Proprietary manufacturing methods will enhance market exclusivity.

MITOCANS VIDEO - http://cancure.com/therapies/mitocans-cnc332/

MITOCANS PROGRAM LEAD CANDIDATE - CNC332

Cancure Limited Series A Capital Raise – November 2015

TARGETED DRUGS IN THE MIX

“Novel Doublet and Triplet Combo Studies Explode in Melanoma” – OncLive, 16 Apr 2015 “… a range of novel combinations of immunotherapies and targeted agents, including treatment triplets, will likely be part of the future paradigm of melanoma therapy as drug discovery in the field continues at a rapid pace.” Jeffrey S. Weber, MD PhD Moffitt Cancer Center US National Cancer Institute

Cancure Limited Series A Capital Raise – November 2015

GLOBAL PIPELINE OF EXPERIMENTAL DRUGS TARGETING MITOCHONDRIA

Drug Company Stage Indications Mechanism Deals

CPI613 Cornerstone Pharmaceuticals Ph2 Pancreas, AML, NSCLC, Lymphoma, Colorectal Inhibition of α-ketoglutarate dehydrogenase Chiesi purchase of Cornerstone US$255M Birionapant Tetralogic Pharmaceuticals Ph2 OvCa, AML Inhibitor of apoptosis proteins (SMAC mimetic) Recent US$50M IPO LCL161 Novartis Ph2 Solid tumours Myeloma Inhibitor of apoptosis proteins (SMAC mimetic)

• Me-344

Mei Pharma Ph1/2 NSCLC, OvCa CaCx Inhibitor of mTORC1 & 2 pathway - MP-MUS Houston Methodist Preclinical

• Monoamine oxidase, mtDNA

acetylation

• DCA

Academic, no patents Ph2 GBM Inhibition of Pyruvate dehydrogenase kinase

• Obatoclax

GeminX (Cephalon) Ph2 Lymphoma Inhibition of BCL-2 Cephalon purchase of GeminX US$225M AT-406 Ascenta Therapeutics Ph1 AML Inhibition of apoptosis proteins

• Gamitrinib

Wistar’s Cancer Center Preclinical

• Inhibition of HSP90

Cancure Limited Series A Capital Raise – November 2015

BOARD & MANAGEMENT

CEO Dr Ian Nisbet, PhD 30+ years of drug development, business development and general management experience in the international biotechnology sector. Scientific Advisor, Director Prof Steven Ralph Therapy inventor. 30+ years experience in biosciences. Internationally recognised expert in cancer immunology. Director Sydney Evans, LLB BCom Legal and accounting expertise. Experienced in mergers and acquisitions. COO, Director Craig Miles 20+ years business development and funds management experience. VP Business Development Christopher Boyer, BS MBA Specialist in the selling of biotechnology, 20+ years spanning discovery, development & commercialisation. Project Manager Dr Andrew Coley, PhD 20+ years early stage biotech development. Cancer & immunology research, project and IP management. VP Manufacturing & QC Dr Stephen Goodall, PhD 30+ years biotechnology development, manufacturing,

• perations and senior

management. Scientific Advisor Prof Jiri Neuzil Therapy inventor. World- leading investigator of mitochondrial biology.

Cancure Limited Series A Capital Raise – November 2015

VALUE REALISATION

• 1. License Drug Candidates

Large biopharmaceutical companies

• 2. Initial Public Offering

Consider market conditions

• 3. Trade Sale

Sale of the whole Cancure business

Cancure is focused on building value to maximise deal potential at optimal timing of 3-5 years.

Cancure Limited Series A Capital Raise – November 2015

CONTACT DETAILS

Chief Operating Officer, Director Craig Miles craig@cancure.com +61 (0) 408 778 797 PO Box 1177, Broadbeach, Queensland, Australia 4218